Fluoxetine and impulsive aggressive behavior in personality-disordered subjects

Archives of General Psychiatry

Volumn 54, Issue 12, 1997, Pages 1081-1088

  Coccaro, Emil F ^a   Kavoussi, Richard J ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGGRESSION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; IMPULSIVENESS; MALE; PERSONALITY DISORDER; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC SYSTEM; SEXUAL DYSFUNCTION; SLEEP DISORDER; TREATMENT OUTCOME;

EID: 0030777605     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.1997.01830240035005     Document Type: Article

References (48)

1. Linnoila M, Virkkunen M, Scheinin M, Nuutila A, Rimon R, Goodwin FK. Low cerebrospinal fluid 5-hydroxyindolacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. Life Sci. 1983;33:2609-2614.
2. Virkkunen M, Rawlins R, Tokola R, Poland RE, Guidotti A, Nemeroff C, Bissette G, Katogeras K, Karonen SL, Linnoila M. CSF biochemistries, glucose metabolism, and diurnal activity rhythms in alcoholic, violent offenders, fire setters, and healthy volunteers. Arch Gen Psychiatry. 1994;51:20-27.
3. Brown GL, Goodwin FK, Ballenger JC, Goyer PF, Major LF. Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychiatry Res. 1979; 1:131-139.
4. Brown GL, Ebert MH, Goyer PF, Jimerson DC, Klein WJ, Bunney WE, Goodwin FK. Aggression, suicide, and serotonin: relationships to CSF amine metabolites. Am J Psychiatry. 1982;139:741-746.
5. Coccaro EF, Siever LJ, Klar H, Maurer G, Cochrane K, Cooper TB, Mohs RC, Davis KL. Serotonergic studies in affective and personality disorder patients: corre lates with suicidal and impulsive aggressive behavior. Arch Gen Psychiatry. 1989; 46:587-599.
6. Moss HB, Yao JK, Panzak GL. Serotonergic responsivity and behavioral dimensions in antisocial personality disorder with substance abuse. Biol Psychiatry, 1990;28:325-338.
7. O'Keane V, Moloney E, O'Neill H, O'Connor A, Smith C, Dinan TG. Blunted prolactin responses to D-fenfluramine in sociopathy: evidence for subsensitivity of central serotonergic function. Br J Psychiatry. 1992;160:643-646.
8. 3H- imipramine binding sites on platelets of conduct disordered children, Neuropsy- chopharmacology. 1987;1:55-62.
9. Birmaher B, Stanley M, Greenhill L, Twomey J, Gavrilescu A, Rabinovich H. Platelet imipramine binding in children and adolescents with impulsive behavior. J Am Acad Child Adolesc Psychiatry. 1990;29.914-918.
10. Marazziti D, Rotondo A, Presta S, Panioli-Guadagnucci ML, Palego L, Conti L Role of serotonin in human aggressive behavior. Aggress Behav. 1993;9:347- 353.
11. Coccaro EF, Gabriel S, Siever LJ. Buspirone challenge: preliminary evidence for a role for central 5-HT-1a receptor function in impulsive aggressive behavior in humans. Psychopharmacol Bull. 1990;26:393-405.
12. Limson R, Goldman D, Roy A, Lamparski D, Ravitz B, Adinoff B, Linnoila M. Personality and cerebrospinal fluid monoamine metabolites in alcoholics and controls. Arch Gen Psychiatry. 1991;48:437-441.
13. Bernstein DP, Handlesman L. The neurobiolopy of substance abuse and personality disorders. In: Ratey JJ, ed. Neuropsychiatry of Behavior Disorders. Cambridge, Mass: Blackwell Science, Inc; 1995:120-148.
14. Kruesi MJP, Rapoport JL, Hamberger S, Hibbs E, Potter WZ, Lenane M, Brown GL. CSF metabolites, aggression, and impulsivity in disruptive behavior disorders of children and adolescents. Arch Gen Psychiatry. 1990;47:419-462.
15. Brown CS, Kent TA, Bryant SG, Gevedon RM, Campbell JL, Felthous AR, Barratt ES, Rose RM. Blood platelet uptake of serotonin in episodic aggression. Psychiatry Res. 1989;27:5-12.
16. Eichelman B. Animal and evolutionary models of impulsive aggression. In: Stein D, Hollander E, eds. Impulsive Aggression and Disorders of Impulse Control. New York, NY: John Wiley & Sons Inc; 1995:59-69.
17. Sheard M, Marini J, Bridges C, Wapner A. The effect of lithium on impulsive aggressive behavior in man. Am J Psychiatry. 1976;133:1409-1413.
18. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine, and tranylcypromine. Arch Gen Psychiatry. 1988;45:111-119.
19. Silver JM, Yudofsky SC. Propranolol in the treatment of chronically hospitalized violent patients. In: Shagass C, Josiassen RC, Bridger WH, Weiss KJ, Stoft D, Simpson GM, eds. Biological Psychiatry. New York, NY: Elsevier Science Inc; 1986:174-176.
20. Teicher MH, Glod CA, Aaronson ST, Gunter PA, Schatzberg AF, Cole JO. Open assessment of the safety and efficacy of thioridazine in the treatment of patients with borderline personality disorder. Psychopharmacol Bull. 1989;25:535-549.
21. Norden MJ. Fluoxetine in borderline personality disorder. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13:885-893.
22. Cornelius JR, Soloff PH, Perel JM, Ulrich RF. Fluoxetine trial in borderline personality disorder. Psychopharmacol Bull 1990;26:151-154.
23. Coccaro EF, Astill JL, Herbert J, Schut A. Fluoxetine treatment of impulsive aggression in DSM-III-R personality disorder patients. J Clin Psychopharmacol. 1990;10:373-375.
24. Markovitz PJ, Calabrese JR, Schulz SC, Meltzer HY. Fluoxetine in borderline and schizotypal personality disorder. Am J Psychiatry. 1991;148:1064-1067.
25. Kavoussi RJ, Liu J, Coccaro EF. An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry. 1994;55:137-141.
26. Fava M, Rosenbaum JF, Pava JA, McCarthy MK, Steingard RJ, Bouffides E. Anger attacks in unipolar depression, 1: clinical correlates and response to fluoxetine treatment. Am J Psychiatry. 1993;150:1158-1163.
27. Heiligenstein JH, Coccaro EF, Potvin JH, Beastey CM, Dornseif BE, Mascia DN. Fluoxetine not associated with increased violence or aggression in controlled clinical trials. Ann Clin Psychiatry. 1992;4:285-295.
28. Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese, Scnwartz J, Miyawaki E. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol. 1995;15:23-29.
29. Perry KW, Fuller RW. Effect of fluoxetine on serotonin and dopamine concentration in microdialysis fluid from rat striatium. Life Sci. 1992;50:1683-1690.
30. Fuller RW. Minireview: uptake inhibitors increase extracellular serotonin concentration measures by brain microdialysis. Life Sci. 1994;55:163-167.
31. Blier P, de Montigny C, Chaput Y. Modifications of the serotonin system by antidepressant treatments: implication for the therapeutic response in major depression. J Clin Psychopharmacol. 1987;7:24S-35S.
32. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised. Washington, DC: American Psychiatric Press; 1987.
33. Coccaro EF, Harvey PD, Kupsaw-Lawrence E, Herbert JL, Bernstein DP. Development of neuropharmacologically based behavioral assessments of impulsive aggressive behavior. J Neuropsychiatry Clin Neurosci. 1991;3:S44-S51.
34. Brown GL, Goodwin FK. Diagnostic, clinical and personality characteristics of aggressive men with low CSF 5-HIAA, Clin Neuropharmacol. 1984;7:S408- S409.
35. 3H-paroxetine binding in the platelet. Aren Gen Psychiatry. 1996;53:531-536.
36. Leckman JF, Sholomskas D, Thompson WD, Belanger A, Weissman MM. Best estimate of lifetime psychiatric diagnosis: a methodologic study. Arch Gen Psychiatry. 1982;39:879-883.
37. Klein DN, Ouimette PC, Kelly HS, Ferro T, Riso LP. Test-retest reliability of team consensus best-estimate diagnoses of axis I and II disorders in a family study. Am J Psychiatry. 1994;151:1043-1047.
38. Spitzer RL, Endicott J. Schedule for Affective Disorders and Schizophrenia. New York, NY: New York State Psychiatric Institute; 1978.
39. Pfohl B, Zimmerman, M. Structured Interview for the Diagnosis of DSM-III-R Personality Disorders. Ames: University of Iowa College of Medicine; 1989.
40. Guy W. ECDEU Manual for Psychopharmacology. Washington, DC: Superintendent of Documents, US Government Printing Office; 1976. US Dept of Health, Education, and Welfare publication ADM 76-338.
41. DeLongis A, Folkman S, Lazarus RS. The impact of daily stress on health and mood: psychological and social resources as mediators. J Pers Soc Psychol 1988; 54:486-495.
42. Suckow RS, Chang M, Cooper TB. A sensitive and selective liquid Chromatographic method using fluorescence detection for plasma fluoxetine and norfluoxetine. Clin Chem. 1992;38:1756-1761.
43. Sheard MH, Marini JL. Treatment of human aggressive behavior, four case studies of the effect of lithium. Compr Psychiatry. 1978;19:37-45.
44. Depue RA, Spoont MR. Conceptualizing a serotonin trait: a behavioral dimension of constraint. Ann N Y Acad Sci. 1986;487:47-62.
45. Coccaro EF. Psychopharmacologic studies in patients with personality disorder: review and perspective. J Pers Disord. Spring 1993(suppl):181-192.
46. Molina VA, Gobaille S, Mandel P. Effects of serotonin-mimetic drugs on mouse- killing behavior. Aggress Behav. 1986;12:201-211.
47. Cornelius JR, Soloff PH, Perel JM, Ulrich RF. Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine. Am J Psychiatry. 1993;150:1843-1848.
48. Stone MH. The role of pharmacotherapy in the treatment of patients with borderline personality disorder. Psychopharmacol Bull. 1989;25:564-571.